May 18, 2021 / 07:00PM GMT
Ravi Misra - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
Hi. Good afternoon. Welcome to the Berenberg Capital Markets Conference USA. We're absolutely thrilled to have the management of Tandem Diabetes here, CFO, Leigh Vosseller; and CAO, Susan Morrison. Thank you for the next kind of 45 minutes of your time. (Operator Instructions)
Questions and Answers:
Ravi Misra - Joh. Berenberg, Gossler & Co. KG, Research Division - AnalystSo I just want to maybe start off setting the picture. You're 1 of 3 insulin pump delivery systems from a noninjection perspective in the United States and worldwide, pretty much one of a handful. Can you maybe talk about the market opportunity as you see it between the type 1 patient and the type 2 patients. Sorry, we have a very excited Tandem investor in the background.
So if we can think about sort of this goal that you've discussed in the past of around 0.5 million patients by 20 (inaudible), how do we think about it from a kind of type 1 versus type 2 perspective? Where do you see the mix
Trustpilot
